FDA's Gene Therapy Chief Vijay Kumar Exits Amid Leadership Changes

By Rachel Kim

Vijay Kumar, M.D., who has been serving as the Acting Super Office Director of the FDA’s Office of Therapeutic Products (OTP), is leaving his position, according to a report by STAT. This departure is part of a larger leadership shake-up at the FDA.

The Office of Therapeutic Products was established in February 2023 to enhance the FDA's capacity for reviewing gene and cell therapies. It was created under the Prescription Drug User Fee Act (PDUFA) VII commitments to centralize and strengthen the Center for Biologics Evaluation and Research's (CBER) review capabilities.

Despite Kumar's exit, there has been no official announcement from the FDA regarding his departure, nor has a successor been named. The FDA's leadership roster still lists Kumar as the Acting Super Office Director of the OTP.

The OTP is composed of six offices, 14 divisions, and 33 branches, reflecting its role in managing the increasing volume of advanced therapy submissions.